ABCG2 p.Gly406Leu

Predicted by SNAP2: A: N (72%), C: D (63%), D: D (85%), E: D (91%), F: D (91%), H: D (91%), I: D (85%), K: D (91%), L: D (85%), M: D (80%), N: D (75%), P: D (85%), Q: D (85%), R: D (91%), S: N (53%), T: D (80%), V: D (75%), W: D (91%), Y: D (91%),
Predicted by PROVEAN: A: N, C: D, D: D, E: D, F: D, H: D, I: D, K: D, L: D, M: D, N: D, P: D, Q: D, R: D, S: N, T: D, V: D, W: D, Y: D,

[switch to compact view]
Comments [show]
Publications
[hide] Polgar O, Robey RW, Morisaki K, Dean M, Michejda C, Sauna ZE, Ambudkar SV, Tarasova N, Bates SE
Mutational analysis of ABCG2: role of the GXXXG motif.
Biochemistry. 2004 Jul 27;43(29):9448-56., 2004-07-27 [PMID:15260487] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Vethanayagam RR, Wang H, Gupta A, Zhang Y, Lewis F, Unadkat JD, Mao Q
Functional analysis of the human variants of breast cancer resistance protein: I206L, N590Y, and D620N.
Drug Metab Dispos. 2005 Jun;33(6):697-705. Epub 2005 Mar 2., [PMID:15743976] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Mao Q, Unadkat JD
Role of the breast cancer resistance protein (ABCG2) in drug transport.
AAPS J. 2005 May 11;7(1):E118-33., [PMID:16146333] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Li YF, Polgar O, Okada M, Esser L, Bates SE, Xia D
Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: a molecular modeling study.
J Mol Graph Model. 2007 Mar;25(6):837-51. Epub 2006 Aug 30., [PMID:17027309] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Hazai E, Bikadi Z
Homology modeling of breast cancer resistance protein (ABCG2).
J Struct Biol. 2008 Apr;162(1):63-74. Epub 2007 Dec 15., [PMID:18249138] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Polgar O, Ierano C, Tamaki A, Stanley B, Ward Y, Xia D, Tarasova N, Robey RW, Bates SE
Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2.
Biochemistry. 2010 Mar 16;49(10):2235-45., 2010-03-16 [PMID:20088606] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Haider AJ, Briggs D, Self TJ, Chilvers HL, Holliday ND, Kerr ID
Dimerization of ABCG2 analysed by bimolecular fluorescence complementation.
PLoS One. 2011;6(10):e25818. Epub 2011 Oct 3., [PMID:21991363] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] George RL, Keenan RT
Genetics of hyperuricemia and gout: implications for the present and future.
Curr Rheumatol Rep. 2013 Feb;15(2):309. doi: 10.1007/s11926-012-0309-8., [PMID:23307580] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Stacy AE, Jansson PJ, Richardson DR
Molecular pharmacology of ABCG2 and its role in chemoresistance.
Mol Pharmacol. 2013 Nov;84(5):655-69. doi: 10.1124/mol.113.088609. Epub 2013 Sep 10., [PMID:24021215] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Szafraniec MJ, Szczygiel M, Urbanska K, Fiedor L
Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).
Drug Metab Rev. 2014 Nov;46(4):459-74. doi: 10.3109/03602532.2014.942037. Epub 2014 Jul 18., [PMID:25036722] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]